* Cambridge NeuroScience Inc., of Cambridge, Mass., was notified by NASDAQ that its stock was to be delisted, effective Jan. 21, for failing to meet minimum $1 bid price requirements. The stock moved to the OTC Bulletin Board, under the symbol CNSI.
* PowderJect Pharmaceuticals plc, of Oxford, England, and its wholly owned subsidiary, PowderJect Vaccines Inc., of Madison, Wis., expanded their March 1998 collaboration with London-based Glaxo Wellcome plc in DNA vaccines. The original deal allowed Glaxo to apply PowderJect technology to hepatitis B. In the new deal, Glaxo exercised an option on another product area and licensed rights to develop another vaccine. Specific targets weren't disclosed.
* Genome Therapeutics Corp., of Waltham, Mass., said it reached the first milestone from its September 1997 genomics collaboration with Schering-Plough Corp., of Madison, N.J. Genome Therapeutics delivered technologies for the rapid identification of novel target genes in two fungal pathogens, Candida albicans and Aspergillus fumigatus.